Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2019 Filed Feb 11, 2019 22:33 UTC |
BRUN LESLIE ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001225208-19-002157 · doc4.xml · derivative · entry 3 BRUN LESLIE A · CIK 0001217068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option became exercisable in equal installments on 05/01/2010, 05/01/2011 and 05/01/2012. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:33 UTC |
BRUN LESLIE ADirector
|
SaleCommon Stock | 3,052 | $77.22 | $235,680.63 |
DisclosureSEC source: 0001225208-19-002157 · doc4.xml · nonDerivative · entry 2 BRUN LESLIE A · CIK 0001217068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948 Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:33 UTC |
BRUN LESLIE ADirector
|
Exercise / conversionCommon Stock | 5,000 | $24.30 | $121,500.00 |
DisclosureSEC source: 0001225208-19-002157 · doc4.xml · nonDerivative · entry 1 BRUN LESLIE A · CIK 0001217068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 22:30 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 231,566 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-19-001889 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,132 Underlying: Common Stock · 231,566 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 22:30 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
SaleCommon Stock | 231,566 | $78.08 | $18,079,654.39 |
DisclosureSEC source: 0001225208-19-001889 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.0000 to $78.3700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 22:30 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 231,566 | $39.29 | $9,098,228.14 |
DisclosureSEC source: 0001225208-19-001889 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,516.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2019 Filed Feb 4, 2019 22:44 UTC |
GLOCER THOMAS HDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-19-001750 · doc4.xml · derivative · entry 5 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 8/4/2011, 8/4/2012 and 8/4/2013. Read SEC document |
| February 04, 2019 Filed Feb 4, 2019 22:44 UTC |
GLOCER THOMAS HDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001225208-19-001750 · doc4.xml · derivative · entry 4 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2010, 5/1/2011 and 5/1/2012. Read SEC document |
| February 04, 2019 Filed Feb 4, 2019 22:44 UTC |
GLOCER THOMAS HDirector
|
SaleCommon Stock | 10,000 | $75.96 | $759,590.00 |
DisclosureSEC source: 0001225208-19-001750 · doc4.xml · nonDerivative · entry 3 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.9500 to $75.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 04, 2019 Filed Feb 4, 2019 22:44 UTC |
GLOCER THOMAS HDirector
|
Exercise / conversionCommon Stock | 5,000 | $24.30 | $121,500.00 |
DisclosureSEC source: 0001225208-19-001750 · doc4.xml · nonDerivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2019 Filed Feb 4, 2019 22:44 UTC |
GLOCER THOMAS HDirector
|
Exercise / conversionCommon Stock | 5,000 | $35.19 | $175,950.00 |
DisclosureSEC source: 0001225208-19-001750 · doc4.xml · nonDerivative · entry 1 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:25 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 441.6961 | $76.41 | $33,750.00 |
DisclosureSEC source: 0001225208-19-000470 · doc4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,242.0401 Underlying: Common Stock · 441.6961 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:27 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 376.2597 | $76.41 | $28,750.00 |
DisclosureSEC source: 0001225208-19-000471 · doc4.xml · derivative · entry 3 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,688.7427 Underlying: Common Stock · 376.2597 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:27 UTC |
Noseworthy John HDirector
|
GrantPhantom Stock · Derivative | 376.2597 | $76.41 | $28,750.00 |
DisclosureSEC source: 0001225208-19-000472 · doc4.xml · derivative · entry 2 Noseworthy John H · CIK 0001706596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,818.0587 Underlying: Common Stock · 376.2597 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:27 UTC |
THULIN INGE GDirector
|
GrantPhantom Stock · Derivative | 376.2597 | $76.41 | $28,750.00 |
DisclosureSEC source: 0001225208-19-000473 · doc4.xml · derivative · entry 2 THULIN INGE G · CIK 0001263739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,887.3177 Underlying: Common Stock · 376.2597 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:27 UTC |
WEEKS WENDELL PDirector
|
GrantPhantom Stock · Derivative | 376.2597 | $76.41 | $28,750.00 |
DisclosureSEC source: 0001225208-19-000474 · doc4.xml · derivative · entry 2 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,415.6397 Underlying: Common Stock · 376.2597 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:27 UTC |
Wendell Peter CDirector
|
GrantPhantom Stock · Derivative | 376.2597 | $76.41 | $28,750.00 |
DisclosureSEC source: 0001225208-19-000475 · doc4.xml · derivative · entry 2 WENDELL PETER C · CIK 0001032635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,461.1547 Underlying: Common Stock · 376.2597 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 08, 2018 Filed Nov 8, 2018 21:31 UTC |
PERLMUTTER ROGER MExe V-P & Pres, MRL
|
Exercise / conversionStock Option (right to buy) · Derivative | 225,443 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-18-015318 · doc4.xml · derivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,443 shares Expires 2023-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016. Read SEC document |
| November 08, 2018 Filed Nov 8, 2018 21:31 UTC |
PERLMUTTER ROGER MExe V-P & Pres, MRL
|
SaleCommon Stock | 225,443 | $75.27 | $16,967,967.40 |
DisclosureSEC source: 0001225208-18-015318 · doc4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,554.968 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.2000 to $75.4500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 08, 2018 Filed Nov 8, 2018 21:31 UTC |
PERLMUTTER ROGER MExe V-P & Pres, MRL
|
Exercise / conversionCommon Stock | 225,443 | $44.98 | $10,140,426.14 |
DisclosureSEC source: 0001225208-18-015318 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,997.968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 21:31 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
Exercise / conversionStock Option (right to buy) · Derivative | 36,218 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-18-015319 · doc4.xml · derivative · entry 3 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,111 Underlying: Common Stock · 36,218 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 21:31 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
SaleCommon Stock | 36,218 | $75.14 | $2,721,348.08 |
DisclosureSEC source: 0001225208-18-015319 · doc4.xml · nonDerivative · entry 2 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,262.984 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.9400 to $75.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 21:31 UTC |
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy
|
Exercise / conversionCommon Stock | 36,218 | $54.68 | $1,980,400.24 |
DisclosureSEC source: 0001225208-18-015319 · doc4.xml · nonDerivative · entry 1 Gerberding Julie L. · CIK 0001628884 · EVP Strat Comm, Gl Pub Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,480.984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:44 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionStock Option (right to buy) · Derivative | 277,879 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-18-015139 · doc4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 277,879 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:44 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 145,135 | $73.66 | $10,691,181.10 |
DisclosureSEC source: 0001225208-18-015139 · doc4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:44 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
SaleCommon Stock | 132,744 | $73.98 | $9,819,763.95 |
DisclosureSEC source: 0001225208-18-015139 · doc4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,135 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:44 UTC |
Schechter Adam HEVP & Pres-Global Human Health
|
Exercise / conversionCommon Stock | 277,879 | $39.29 | $10,917,865.91 |
DisclosureSEC source: 0001225208-18-015139 · doc4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · EVP & Pres-Global Human Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 21:07 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 18,110 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-18-015067 · doc4.xml · derivative · entry 8 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,055 Underlying: Common Stock · 18,110 shares Expires 2026-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 21:07 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,706 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-18-015067 · doc4.xml · derivative · entry 7 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,412 Underlying: Common Stock · 5,706 shares Expires 2027-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 21:07 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 23,220 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-18-015067 · doc4.xml · derivative · entry 6 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,220 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 21:07 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
SaleCommon Stock | 47,036 | $74.33 | $3,496,157.66 |
DisclosureSEC source: 0001225208-18-015067 · doc4.xml · nonDerivative · entry 4 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,770.119 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.1200 to $74.4500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 21:07 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Exercise / conversionCommon Stock | 5,706 | $63.97 | $365,012.82 |
DisclosureSEC source: 0001225208-18-015067 · doc4.xml · nonDerivative · entry 3 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,806.119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 21:07 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Exercise / conversionCommon Stock | 18,110 | $54.68 | $990,254.80 |
DisclosureSEC source: 0001225208-18-015067 · doc4.xml · nonDerivative · entry 2 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,100.119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2018 Filed Nov 1, 2018 21:07 UTC |
Watson AshleySVP Chief Ethics & Com Officer
|
Exercise / conversionCommon Stock | 23,220 | $59.86 | $1,389,949.20 |
DisclosureSEC source: 0001225208-18-015067 · doc4.xml · nonDerivative · entry 1 Watson Ashley · CIK 0001708109 · SVP Chief Ethics & Com Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,990.119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:03 UTC |
Scholefield James HEVP,Chief Info&Digital Officer
|
GrantStock Option (right to buy) · Derivative | 47,456 | $0.00 Strike: $72.87 | $0.00 |
DisclosureSEC source: 0001225208-18-015063 · doc4.xml · derivative · entry 2 Scholefield James H · CIK 0001720922 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,456 Underlying: Common Stock · 47,456 shares Expires 2028-10-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:03 UTC |
Scholefield James HEVP,Chief Info&Digital Officer
|
GrantRestricted Stock Unit · Derivative | 34,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015063 · doc4.xml · derivative · entry 1 Scholefield James H · CIK 0001720922 · EVP,Chief Info&Digital Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,308 Underlying: Common Stock · 34,308 shares Expires 2021-10-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:05 UTC |
MIZELL STEVENEVP, Human Resources
|
GrantStock Option (right to buy) · Derivative | 51,252 | $0.00 Strike: $72.87 | $0.00 |
DisclosureSEC source: 0001225208-18-015064 · doc4.xml · derivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,252 Underlying: Common Stock · 51,252 shares Expires 2028-10-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:05 UTC |
MIZELL STEVENEVP, Human Resources
|
GrantRestricted Stock Unit · Derivative | 13,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015064 · doc4.xml · derivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,723 Underlying: Common Stock · 13,723 shares Expires 2021-10-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:07 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
Exercise / conversionStock Option (right to buy) · Derivative | 25,467 | $0.00 Strike: $34.19 | $0.00 |
DisclosureSEC source: 0001225208-18-015068 · doc4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,467 shares Expires 2021-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option became exercisable in equal installments on 11/2/2012, 11/2/2013 and 11/2/2014. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:07 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
SaleCommon Stock | 25,467 | $72.00 | $1,833,738.60 |
DisclosureSEC source: 0001225208-18-015068 · doc4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,667.828 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.0000 to $72.0150, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 30, 2018 Filed Nov 1, 2018 21:07 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Health
|
Exercise / conversionCommon Stock | 25,467 | $34.19 | $870,716.73 |
DisclosureSEC source: 0001225208-18-015068 · doc4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,134.828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:26 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 279,850 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-18-014342 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 279,850 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:26 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
SaleCommon Stock | 279,850 | $72.07 | $20,168,257.79 |
DisclosureSEC source: 0001225208-18-014342 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 691,950.063 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.17, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| October 02, 2018 Filed Oct 3, 2018 21:26 UTC |
FRAZIER KENNETH CDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 279,850 | $36.56 | $10,231,316.00 |
DisclosureSEC source: 0001225208-18-014342 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,800.063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:38 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 475.7542 | $70.94 | $33,750.00 |
DisclosureSEC source: 0001225208-18-014113 · doc4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,388.7128 Underlying: Common Stock · 475.7542 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:38 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 405.2721 | $70.94 | $28,750.00 |
DisclosureSEC source: 0001225208-18-014114 · doc4.xml · derivative · entry 3 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,776.1184 Underlying: Common Stock · 405.2721 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:39 UTC |
Noseworthy John HDirector
|
GrantPhantom Stock · Derivative | 405.2721 | $70.94 | $28,750.00 |
DisclosureSEC source: 0001225208-18-014115 · doc4.xml · derivative · entry 2 Noseworthy John H · CIK 0001706596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,387.8554 Underlying: Common Stock · 405.2721 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:39 UTC |
THULIN INGE GDirector
|
GrantPhantom Stock · Derivative | 405.2721 | $70.94 | $28,750.00 |
DisclosureSEC source: 0001225208-18-014116 · doc4.xml · derivative · entry 2 THULIN INGE G · CIK 0001263739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,483.4984 Underlying: Common Stock · 405.2721 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:39 UTC |
WEEKS WENDELL PDirector
|
GrantPhantom Stock · Derivative | 405.2721 | $70.94 | $28,750.00 |
DisclosureSEC source: 0001225208-18-014117 · doc4.xml · derivative · entry 2 WEEKS WENDELL P · CIK 0001206158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,471.2864 Underlying: Common Stock · 405.2721 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:39 UTC |
Wendell Peter CDirector
|
GrantPhantom Stock · Derivative | 405.2721 | $70.94 | $28,750.00 |
DisclosureSEC source: 0001225208-18-014118 · doc4.xml · derivative · entry 2 WENDELL PETER C · CIK 0001032635 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,509.7834 Underlying: Common Stock · 405.2721 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.